Oruka Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	2018 - 2014
Net Income	-7.2	-5.34	-9.93	-19.32	-9.74	-5.48	Upgrade
Depreciation & Amortization	0.08	0.11	0.11	0.09	0.09	0.09	Upgrade
Share-Based Compensation	0.52	0.69	0.56	0.5	0.04	0.15	Upgrade
Other Operating Activities	-0.29	-0.47	-1.66	-0.03	1.88	0.44	Upgrade
Operating Cash Flow	-6.89	-5.01	-10.91	-18.76	-7.73	-4.8	Upgrade
Capital Expenditures	0	0	-0	-0.04	-0.02	-0	Upgrade
Investing Cash Flow	0	0	-0	-0.04	-0.02	-0	Upgrade
Share Issuance / Repurchase	0.01	0	0	24.07	50.89	7.28	Upgrade
Debt Issued / Paid	0	0	0	0	-0.41	-0.35	Upgrade
Other Financing Activities	-	-	-	-0.98	-2.03	-0.37	Upgrade
Financing Cash Flow	0.01	0	0	23.09	48.45	6.56	Upgrade
Net Cash Flow	-6.87	-5.01	-10.91	4.29	40.71	1.76	Upgrade
Free Cash Flow	-6.89	-5.01	-10.91	-18.81	-7.74	-4.81	Upgrade
Free Cash Flow Per Share	-5.70	-4.17	-9.09	-16.23	-19.73	-43.64	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).